Re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–293

Re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–293

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European urology 2022-05, Vol.81 (5), p.e123-e123
Hauptverfasser: Dong, Chen, Chen, Sung-Lang, Sung, Wen-Wei
Format: Artikel
Sprache:eng
Schlagworte:
Androgen Antagonists - therapeutic use
Clinical Trials, Phase II as Topic
COVID-19 - drug therapy
Hormone Replacement Therapy
Humans
Letter to the Editor
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e123
container_issue 5
container_start_page e123
container_title European urology
container_volume 81
creator Dong, Chen
Chen, Sung-Lang
Sung, Wen-Wei
description
doi_str_mv 10.1016/j.eururo.2022.01.048
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8813564</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0302283822016062</els_id><sourcerecordid>2630921923</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-fd621ecba1a649daf33baecc1f983298a612e76b751afe39bdc68608116a48053</originalsourceid><addsrcrecordid>eNp9Uttu00AQtRCIhsIfIDSPPMRmL7azLlKlkJoSUSgqaXlcre1xspGzG3btSHnjH_gKvoM_QXwItlIKvPC0Ws2Zc2bOnCB4SklECU1frCPsXOdsxAhjEaERicW9YETFhIeTJCX3gxHhhIVMcHEUPPJ-TQjhScYfBkc8oYLSLB4FP6_wBN4qpw18wub7NzOGvCgUXFmPplLNGN6ppek8nGvvD3VsQTURTOHDSnkEBgunVQO2hnaFkNc1lu3wm5pWK1M5u0QDixU6td2DNTC7vJmfhTSDy64t7abXf28h3-kKTYlD4ys0WOt2DB-77da6Fiso9pBve8RG28Yu99DzwtzAjW6dhTPVqgjyzsG1s_1kgyEvBT1hIvnx5SvL-OPgQa0aj09u3-Pg-nW-mL0JLy7P57PpRVjGKW_DukoZxbJQVKVxVqma80JhWdI6E5xlQqWU4SQtJglVNfKsqMpUpKR3MlWxIAk_Dk4PvNuu2GBVommdauTW6Y1ye2mVlv9WjF7Jpd1JIShP0rgneH5L4OznDn0rN9qX2DTKoO28ZCknGaMZ4z00PkBLZ713WN_JUCKHgMi1PAREDn5IQmUfkL7t2d8j3jX9TsSfHbA3aqfRSV_q4TKVdv1hZWX1_xV-ASM-z1M</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2630921923</pqid></control><display><type>article</type><title>Re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–293</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Dong, Chen ; Chen, Sung-Lang ; Sung, Wen-Wei</creator><creatorcontrib>Dong, Chen ; Chen, Sung-Lang ; Sung, Wen-Wei</creatorcontrib><identifier>ISSN: 0302-2838</identifier><identifier>EISSN: 1873-7560</identifier><identifier>DOI: 10.1016/j.eururo.2022.01.048</identifier><identifier>PMID: 35181194</identifier><language>eng</language><publisher>Switzerland: Elsevier B.V</publisher><subject>Androgen Antagonists - therapeutic use ; Clinical Trials, Phase II as Topic ; COVID-19 - drug therapy ; Hormone Replacement Therapy ; Humans ; Letter to the Editor</subject><ispartof>European urology, 2022-05, Vol.81 (5), p.e123-e123</ispartof><rights>2022 European Association of Urology</rights><rights>2022 European Association of Urology. Published by Elsevier B.V. All rights reserved. 2022 European Association of Urology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-fd621ecba1a649daf33baecc1f983298a612e76b751afe39bdc68608116a48053</citedby><cites>FETCH-LOGICAL-c463t-fd621ecba1a649daf33baecc1f983298a612e76b751afe39bdc68608116a48053</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0302283822016062$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35181194$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dong, Chen</creatorcontrib><creatorcontrib>Chen, Sung-Lang</creatorcontrib><creatorcontrib>Sung, Wen-Wei</creatorcontrib><title>Re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–293</title><title>European urology</title><addtitle>Eur Urol</addtitle><subject>Androgen Antagonists - therapeutic use</subject><subject>Clinical Trials, Phase II as Topic</subject><subject>COVID-19 - drug therapy</subject><subject>Hormone Replacement Therapy</subject><subject>Humans</subject><subject>Letter to the Editor</subject><issn>0302-2838</issn><issn>1873-7560</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9Uttu00AQtRCIhsIfIDSPPMRmL7azLlKlkJoSUSgqaXlcre1xspGzG3btSHnjH_gKvoM_QXwItlIKvPC0Ws2Zc2bOnCB4SklECU1frCPsXOdsxAhjEaERicW9YETFhIeTJCX3gxHhhIVMcHEUPPJ-TQjhScYfBkc8oYLSLB4FP6_wBN4qpw18wub7NzOGvCgUXFmPplLNGN6ppek8nGvvD3VsQTURTOHDSnkEBgunVQO2hnaFkNc1lu3wm5pWK1M5u0QDixU6td2DNTC7vJmfhTSDy64t7abXf28h3-kKTYlD4ys0WOt2DB-77da6Fiso9pBve8RG28Yu99DzwtzAjW6dhTPVqgjyzsG1s_1kgyEvBT1hIvnx5SvL-OPgQa0aj09u3-Pg-nW-mL0JLy7P57PpRVjGKW_DukoZxbJQVKVxVqma80JhWdI6E5xlQqWU4SQtJglVNfKsqMpUpKR3MlWxIAk_Dk4PvNuu2GBVommdauTW6Y1ye2mVlv9WjF7Jpd1JIShP0rgneH5L4OznDn0rN9qX2DTKoO28ZCknGaMZ4z00PkBLZ713WN_JUCKHgMi1PAREDn5IQmUfkL7t2d8j3jX9TsSfHbA3aqfRSV_q4TKVdv1hZWX1_xV-ASM-z1M</recordid><startdate>20220501</startdate><enddate>20220501</enddate><creator>Dong, Chen</creator><creator>Chen, Sung-Lang</creator><creator>Sung, Wen-Wei</creator><general>Elsevier B.V</general><general>European Association of Urology. Published by Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220501</creationdate><title>Re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–293</title><author>Dong, Chen ; Chen, Sung-Lang ; Sung, Wen-Wei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-fd621ecba1a649daf33baecc1f983298a612e76b751afe39bdc68608116a48053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Androgen Antagonists - therapeutic use</topic><topic>Clinical Trials, Phase II as Topic</topic><topic>COVID-19 - drug therapy</topic><topic>Hormone Replacement Therapy</topic><topic>Humans</topic><topic>Letter to the Editor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dong, Chen</creatorcontrib><creatorcontrib>Chen, Sung-Lang</creatorcontrib><creatorcontrib>Sung, Wen-Wei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dong, Chen</au><au>Chen, Sung-Lang</au><au>Sung, Wen-Wei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–293</atitle><jtitle>European urology</jtitle><addtitle>Eur Urol</addtitle><date>2022-05-01</date><risdate>2022</risdate><volume>81</volume><issue>5</issue><spage>e123</spage><epage>e123</epage><pages>e123-e123</pages><issn>0302-2838</issn><eissn>1873-7560</eissn><cop>Switzerland</cop><pub>Elsevier B.V</pub><pmid>35181194</pmid><doi>10.1016/j.eururo.2022.01.048</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0302-2838
ispartof European urology, 2022-05, Vol.81 (5), p.e123-e123
issn 0302-2838
1873-7560
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8813564
source MEDLINE; Elsevier ScienceDirect Journals
subjects Androgen Antagonists - therapeutic use
Clinical Trials, Phase II as Topic
COVID-19 - drug therapy
Hormone Replacement Therapy
Humans
Letter to the Editor
title Re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–293
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T05%3A11%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Re:%20Karin%20Wel%C3%A9n,%20Ebba%20Rosendal,%20Magnus%20Gissl%C3%A9n,%20et%20al.%20A%20Phase%202%20Trial%20of%20the%20Effect%20of%20Antiandrogen%20Therapy%20on%20COVID-19%20Outcome:%20No%20Evidence%20of%20Benefit,%20Supported%20by%20Epidemiology%20and%20In%20Vitro%20Data.%20Eur%20Urol.%202022;81:285%E2%80%93293&rft.jtitle=European%20urology&rft.au=Dong,%20Chen&rft.date=2022-05-01&rft.volume=81&rft.issue=5&rft.spage=e123&rft.epage=e123&rft.pages=e123-e123&rft.issn=0302-2838&rft.eissn=1873-7560&rft_id=info:doi/10.1016/j.eururo.2022.01.048&rft_dat=%3Cproquest_pubme%3E2630921923%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2630921923&rft_id=info:pmid/35181194&rft_els_id=S0302283822016062&rfr_iscdi=true